Survivin - The inconvenient IAP

Seminars in Cell and Developmental Biology

Volumn 39, Issue , 2015, Pages 91-96

  Altieri, Dario C ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer; Cell division; IAP; Mitotic catastrophe; Survivin

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN; SURVIVIN; BIRC5 PROTEIN, HUMAN;

APOPTOSIS; CELL DIVISION; CELL MOTILITY; CELL SURVIVAL; HUMAN; METASTASIS; REVIEW; STEM CELL; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIVISION; CELL SURVIVAL; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84928211026     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.12.007     Document Type: Review

References (114)

1. Srinivasula S.M., Ashwell J.D. IAPs: what's in a name?. Mol Cell 2008, 30:123-135.
2. Stauber R.H., Mann W., Knauer S.K. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007, 67:5999-6002.
3. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009.
4. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70.
5. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14:5000-5005.
6. Singh N., Subramanian K., Kanwar R.K., Cheung C.H., Kanwar J.R. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers. Drug Discov Today 2014.
7. Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., Noel J.P. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000, 7:602-608.
8. Bourhis E., Hymowitz S.G., Cochran A.G. The mitotic regulator survivin binds as a monomer to its functional interactor Borealin. J Biol Chem 2007, 282:35018-35023.
9. Jeyaprakash A.A., Klein U.R., Lindner D., Ebert J., Nigg E.A., Conti E. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel Together. Cell 2007, 131:271-285.
10. Engelsma D., Rodriguez J.A., Fish A., Giaccone G., Fornerod M. Homodimerization antagonizes nuclear export of survivin. Traffic 2007, 8:1495-1502.
11. Pavlyukov M.S., Antipova N.V., Balashova M.V., Vinogradova T.V., Kopantzev E.P., Shakhparonov M.I. Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem 2011, 286:23296-23307.
12. Boidot R., Vegran F., Lizard-Nacol S. Transcriptional regulation of the survivin gene. Mol Biol Rep 2014, 41:233-240.
13. Rauch A., Hennig D., Schafer C., Wirth M., Marx C., Heinzel T., et al. Survivin and YM155: how faithful is the liaison?. Biochim Biophys Acta 2014, 1845:202-220.
14. Li F., Altieri D.C. Transcriptional analysis of human survivin gene expression. Biochem J 1999, 344(Pt 2):305-311.
15. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
16. Mirza A., McGuirk M., Hockenberry T.N., Wu Q., Ashar H., Black S., et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002, 21:2613-2622.
17. Hoffman W.H., Biade S., Zilfou J.T., Chen J., Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002, 277:3247-3257.
18. Guha M., Plescia J., Leav I., Li J., Languino L.R., Altieri D.C. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res 2009, 69:4954-4958.
19. Wang R.H., Zheng Y., Kim H.S., Xu X., Cao L., Luhasen T., et al. Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis. Mol Cell 2008, 32:11-20.
20. Guha M., Altieri D.C. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 2009, 8:2708-2710.
21. Nogueira-Ferreira R., Vitorino R., Ferreira-Pinto M.J., Ferreira R., Henriques-Coelho T. Exploring the role of post-translational modifications on protein-protein interactions with survivin. Arch Biochem Biophys 2013, 538:64-70.
22. cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 2000, 97:13103-13107.
23. Goga A., Yang D., Tward A.D., Morgan D.O., Bishop J.M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007, 13:820-827.
24. Barrett R.M., Osborne T.P., Wheatley S.P. Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity. Cell Cycle 2009, 8:278-283.
25. Wheatley S.P., Barrett R.M., Andrews P.D., Medema R.H., Morley S.J., Swedlow J.R., et al. Phosphorylation by Aurora-B negatively regulates survivin function during mitosis. Cell Cycle 2007, 6.
26. Wheatley S.P., Henzing A.J., Dodson H., Khaled W., Earnshaw W.C. Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo. J Biol Chem 2004, 279:5655-5660.
27. Barrett R.M., Colnaghi R., Wheatley S.P. Threonine 48 in the BIR domain of survivin is critical to its mitotic and anti-apoptotic activities and can be phosphorylated by CK2 in vitro. Cell Cycle 2011, 10:538-548.
28. Dohi T., Xia F., Altieri D.C. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 2007, 27:17-28.
29. Riolo M.T., Cooper Z.A., Holloway M.P., Cheng Y., Bianchi C., Yakirevich E., et al. Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in breast cancer. J Biol Chem 2012, 287:10885-10893.
30. Lens S.M., Vader G., Medema R.H. The case for survivin as mitotic regulator. Curr Opin Cell Biol 2006, 18:616-622.
31. Altieri D.C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006, 18:609-615.
32. Uren A.G., Wong L., Pakusch M., Fowler K.J., Burrows F.J., Vaux D.L., et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000, 10:1319-1328.
33. Okada H., Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004, 4:592-603.
34. Gurbuxani S., Xu Y., Keerthivasan G., Wickrema A., Crispino J.D. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A 2005, 102:11480-11485.
35. Fraser A.G., James C., Evan G.I., Hengartner M.O. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis. Curr Biol 1999, 9:292-301.
36. Speliotes E.K., Uren A., Vaux D., Horvitz H.R. The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol Cell 2000, 6:211-223.
37. Huang H.K., Bailis J.M., Leverson J.D., Gomez E.B., Forsburg S.L., Hunter T. Suppressors of Bir1p (Survivin) identify roles for the chromosomal passenger protein Pic1p (INCENP) and the replication initiation factor Psf2p in chromosome segregation. Mol Cell Biol 2005, 25:9000-9015.
38. Carmena M., Wheelock M., Funabiki H., Earnshaw W.C. The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol 2012, 13:789-803.
39. Vong Q.P., Cao K., Li H.Y., Iglesias P.A., Zheng Y. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 2005, 310:1499-1504.
40. Yamagishi Y., Honda T., Tanno Y., Watanabe Y. Two histone marks establish the inner centromere and chromosome bi-orientation. Science 2010, 330:239-243.
41. Kelly A.E., Ghenoiu C., Xue J.Z., Zierhut C., Kimura H., Funabiki H. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science 2010, 330:235-239.
42. Wang F., Dai J., Daum J.R., Niedzialkowska E., Banerjee B., Stukenberg P.T., et al. Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis. Science 2010, 330:231-235.
43. Kawashima S.A., Yamagishi Y., Honda T., Ishiguro K., Watanabe Y. Phosphorylation of H2A by Bub1 prevents chromosomal instability through localizing shugoshin. Science 2010, 327:172-177.
44. Campbell C.S., Desai A. Tension sensing by Aurora B kinase is independent of survivin-based centromere localization. Nature 2013, 497:118-121.
45. Jeyaprakash A.A., Basquin C., Jayachandran U., Conti E. Structural basis for the recognition of phosphorylated histone h3 by the survivin subunit of the chromosomal passenger complex. Structure 2011, 19:1625-1634.
46. Du J., Kelly A.E., Funabiki H., Patel D.J. Structural basis for recognition of H3T3ph and Smac/DIABLO N-terminal peptides by human Survivin. Structure 2012, 20:185-195.
47. Song Z., Yao X., Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003, 278:23130-23140.
48. Ceballos-Cancino G., Espinosa M., Maldonado V., Melendez-Zajgla J. Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene 2007, 26:7569-7575.
49. Sun C., Nettesheim D., Liu Z., Olejniczak E.T. Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry 2005, 44:11-17.
50. Xia F., Canovas P.M., Guadagno T.M., Altieri D.C. A survivin-ran complex regulates spindle formation in tumor cells. Mol Cell Biol 2008, 28:5299-5311.
51. Iyer J., Tsai M.Y. A novel role for TPX2 as a scaffold and co-activator protein of the Chromosomal Passenger Complex. Cell Signal 2012, 24:1677-1689.
52. Li F., Ackermann E.J., Bennett C.F., Rothermel A.L., Plescia J., Tognin S., et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999, 1:461-466.
53. Giodini A., Kallio M.J., Wall N.R., Gorbsky G.J., Tognin S., Marchisio P.C., et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002, 62:2462-2467.
54. Rosa J., Canovas P., Islam A., Altieri D.C., Doxsey S.J. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell 2006, 17:1483-1493.
55. Saito T., Hama S., Izumi H., Yamasaki F., Kajiwara Y., Matsuura S., et al. Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells. Br J Cancer 2008, 98:345-355.
56. Okada H., Bakal C., Shahinian A., Elia A., Wakeham A., Suh W.K., et al. Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med 2004, 199:399-410.
57. Aboualaiwi W.A., Muntean B.S., Ratnam S., Joe B., Liu L., Booth R.L., et al. Survivin-induced abnormal ploidy contributes to cystic kidney and aneurysm formation. Circulation 2014, 129:660-672.
58. Yan J., Yan F., Li Z., Sinnott B., Cappell K.M., Yu Y., et al. The 3M complex maintains microtubule and genome integrity. Mol Cell 2014, 54:791-804.
59. Huber C., Dias-Santagata D., Glaser A., O'Sullivan J., Brauner R., Wu K., et al. Identification of mutations in CUL7 in 3-M syndrome. Nat Genet 2005, 37:1119-1124.
60. Skaar J.R., Florens L., Tsutsumi T., Arai T., Tron A., Swanson S.K., et al. PARC and CUL7 form atypical cullin RING ligase complexes. Cancer Res 2007, 67:2006-2014.
61. Li Z., Pei X.H., Yan J., Yan F., Cappell K.M., Whitehurst A.W., et al. CUL9 mediates the functions of the 3M complex and ubiquitylates survivin to maintain genome integrity. Mol Cell 2014, 54:805-819.
62. Adams R.R., Carmena M., Earnshaw W.C. Chromosomal passengers and the (Aurora) ABCs of mitosis. Trends Cell Biol 2001, 11:49-54.
63. Vitale I., Galluzzi L., Castedo M., Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011, 12:385-392.
64. Lamers F., van der Ploeg I., Schild L., Ebus M.E., Koster J., Hansen B.R., et al. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe. Endocr Relat Cancer 2011, 18:657-668.
65. Beltrami E., Plescia J., Wilkinson J.C., Duckett C.S., Altieri D.C. Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J Biol Chem 2004, 279:2077-2084.
66. Maskey D., Yousefi S., Schmid I., Zlobec I., Perren A., Friis R., et al. ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat Commun 2013, 4:2130.
67. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004, 10:262-267.
68. Xia F., Altieri D.C. Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res 2006, 66:3392-3395.
69. Adida C., Crotty P.L., McGrath J., Berrebi D., Diebold J., Altieri D.C. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998, 152:43-49.
70. Kim P.J., Plescia J., Clevers H., Fearon E.R., Altieri D.C. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003, 362:205-209.
71. Brun S.N., Markant S.L., Esparza L.A., Garcia G., Terry D., Huang J.M., et al. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. Oncogene 2014, 0.
72. Tsuneki M., Madri J.A. Adhesion molecule-mediated hippo pathway modulates hemangioendothelioma cell behavior. Mol Cell Biol 2014, 34:4485-4499.
73. Lee C.W., Raskett C.M., Prudovsky I., Altieri D.C. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res 2008, 68:5273-5281.
74. Blum B., Bar-Nur O., Golan-Lev T., Benvenisty N. The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat Biotechnol 2009, 27:281-287.
75. Filion T.M., Qiao M., Ghule P.N., Mandeville M., van Wijnen A.J., Stein J.L., et al. Survival responses of human embryonic stem cells to DNA damage. J Cell Physiol 2009, 220:586-592.
76. Coumoul X., Li W., Wang R.H., Deng C. Inducible suppression of Fgfr2 and Survivin in ES cells using a combination of the RNA interference (RNAi) and the Cre-LoxP system. Nucleic Acids Res 2004, 32:e85.
77. Mull A.N., Klar A., Navara C.S. Differential localization and high expression of SURVIVIN splice variants in human embryonic stem cells but not in differentiated cells implicate a role for SURVIVIN in pluripotency. Stem Cell Res 2014, 12:539-549.
78. Kapinas K., Kim H., Mandeville M., Martin-Buley L.A., Croce C.M., Lian J.B., et al. microRNA-mediated survivin control of pluripotency. J Cell Physiol 2015, 230:63-70.
79. Miranda C.J., Braun L., Jiang Y., Hester M.E., Zhang L., Riolo M., et al. Aging brain microenvironment decreases hippocampal neurogenesis through Wnt-mediated survivin signaling. Aging Cell 2012, 11:542-552.
80. Leung C.G., Xu Y., Mularski B., Liu H., Gurbuxani S., Crispino J.D. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med 2007, 204:1603-1611.
81. Fukuda S., Hoggatt J., Singh P., Abe M., Speth J.M., Hu P., et al. Survivin modulates genes with divergent molecular functions and regulates proliferation of hematopoietic stem cells through Evi-1. Leukemia 2014.
82. Marconi A., Dallaglio K., Lotti R., Vaschieri C., Truzzi F., Fantini F., et al. Survivin identifies keratinocyte stem cells and is downregulated by anti-beta1 integrin during anoikis. Stem Cells 2007, 25:149-155.
83. George R.J., Sturmoski M.A., May R., Sureban S.M., Dieckgraefe B.K., Anant S., et al. Loss of p21Waf1/Cip1/Sdi1 enhances intestinal stem cell survival following radiation injury. Am J Physiol Gastrointest Liver Physiol 2009, 296:G245-G254.
84. Small S., Keerthivasan G., Huang Z., Gurbuxani S., Crispino J.D. Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia 2010, 24:1920-1926.
85. Park E., Gang E.J., Hsieh Y.T., Schaefer P., Chae S., Klemm L., et al. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011, 118:2191-2199.
86. Hipp N.I., Christner L., Wirth T., Mueller-Klieser W., Walenta S., Schrock E., et al. MYCN and survivin cooperatively contribute to malignant transformation of fibroblasts. Carcinogenesis 2014, 35:479-488.
87. Guvenc H., Pavlyukov M.S., Joshi K., Kurt H., Banasavadi-Siddegowda Y.K., Mao P., et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res 2013, 19:631-642.
88. Carter B.Z., Qiu Y., Huang X., Diao L., Zhang N., Coombes K.R., et al. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 2012, 120:173-180.
89. Lv S., Dai C., Liu Y., Shi R., Tang Z., Han M., et al. The impact of survivin on prognosis and clinicopathology of glioma patients: a systematic meta-analysis. Mol Neurobiol 2014, 1-6.
90. Lee M.O., Moon S.H., Jeong H.C., Yi J.Y., Lee T.H., Shim S.H., et al. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc Natl Acad Sci U S A 2013, 110:E3281-E3290.
91. Ahmed A.U., Thaci B., Tobias A.L., Auffinger B., Zhang L., Cheng Y., et al. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst 2013, 105:968-977.
92. Feng R., Zhou S., Liu Y., Song D., Luan Z., Dai X., et al. Sox2 protects neural stem cells from apoptosis via up-regulating survivin expression. Biochem J 2013, 450:459-468.
93. Wang H., Holloway M.P., Ma L., Cooper Z.A., Riolo M., Samkari A., et al. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 2010, 285:36129-36137.
94. Salz W., Eisenberg D., Plescia J., Garlick D.S., Weiss R.M., Wu X.R., et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res 2005, 65:3531-3534.
95. Rodel F., Sprenger T., Kaina B., Liersch T., Rodel C., Fulda S., et al. Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Curr Med Chem 2012, 19:3679-3688.
96. Min L., Ji Y., Bakiri L., Qiu Z., Cen J., Chen X., et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol 2012, 14:1203-1211.
97. Li Y., Ma X., Wu X., Liu X., Liu L. Prognostic significance of survivin in breast cancer: meta-analysis. Breast J 2014, 20:514-524.
98. Goossens-Beumer I.J., Zeestraten E.C., Benard A., Christen T., Reimers M.S., Keijzer R., et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer 2014, 110:2935-2944.
99. Chen J., Li T., Liu Q., Jiao H., Yang W., Liu X., et al. Clinical and prognostic significance of HIF-1alpha, PTEN, CD44v6, and survivin for gastric cancer: a meta-analysis. PLOS ONE 2014, 9:e91842.
100. Selemetjev S., Dencic T.I., Marecko I., Jankovic J., Paunovic I., Savin S., et al. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma. Pathol Res Pract 2014, 210:30-34.
101. Cao M., Yie S.M., Wu S.M., Chen S., Lou B., He X., et al. Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis 2009, 26:751-758.
102. Yie S.M., Lou B., Ye S.R., He X., Cao M., Xie K., et al. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer 2009, 63:284-290.
103. Fulda S. Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists. Oncogene 2014, 33:671-676.
104. Oberoi T.K., Dogan T., Hocking J.C., Scholz R.P., Mooz J., Anderson C.L., et al. IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation. EMBO J 2012, 31:14-28.
105. Dogan T., Harms G.S., Hekman M., Karreman C., Oberoi T.K., Alnemri E.S., et al. X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat Cell Biol 2008, 10:1447-1455.
106. Liu J., Zhang D., Luo W., Yu Y., Yu J., Li J., et al. X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via Rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton. J Biol Chem 2011, 286:15630-15640.
107. Yu J., Zhang D., Liu J., Li J., Yu Y., Wu X.R., et al. RhoGDI SUMOylation at Lys-138 increases its binding activity to Rho GTPase and its inhibiting cancer cell motility. J Biol Chem 2012, 287:13752-13760.
108. Geisbrecht E.R., Montell D.J. A role for Drosophila IAP1-mediated caspase inhibition in Rac-dependent cell migration. Cell 2004, 118:111-125.
109. Ye Q., Cai W., Zheng Y., Evers B.M., She Q.B. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 2014, 33:1828-1839.
110. Gao F., Zhang Y., Yang F., Wang P., Wang W., Su Y., et al. Survivin promotes the invasion of human colon carcinoma cells by regulating the expression of MMP7. Mol Med Rep 2014, 9:825-830.
111. McKenzie J.A., Liu T., Goodson A.G., Grossman D. Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res 2010, 70:7927-7937.
112. McKenzie J.A., Liu T., Jung J.Y., Jones B.B., Ekiz H.A., Welm A.L., et al. Survivin promotion of melanoma metastasis requires upregulation of alpha5 integrin. Carcinogenesis 2013, 34:2137-2144.
113. Mehrotra S., Languino L.R., Raskett C.M., Mercurio A.M., Dohi T., Altieri D.C. IAP regulation of metastasis. Cancer Cell 2010, 17:53-64.
114. Nabzdyk C.S., Lancero H., Nguyen K.P., Salek S., Conte M.S. RNA interference-mediated survivin gene knockdown induces growth arrest and reduced migration of vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2011, 301:H1841-H1849.